Irreversible inhibition of Bruton’s tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). However, ibrutinib also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback